StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research note released on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Stock Performance
Shares of MNOV opened at $1.30 on Friday. MediciNova has a 1 year low of $1.26 and a 1 year high of $2.56. The company has a market cap of $63.77 million, a price-to-earnings ratio of -7.65 and a beta of 0.72. The firm has a fifty day moving average of $1.37 and a 200-day moving average of $1.40.
MediciNova (NASDAQ:MNOV – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Analysts predict that MediciNova will post -0.23 EPS for the current year.
Institutional Investors Weigh In On MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
- Five stocks we like better than MediciNova
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Survey: Top 175 Fittest Retirement Locations in America
- How to Start Investing in Real Estate
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Most Volatile Stocks, What Investors Need to Know
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.